Recursion Pharmaceuticals Inc是一家临床阶段的生物技术公司,通过整合生物学、化学、自动化、机器学习和工程技术来解码生物学,以实现药物发现的工业化。该公司的平台包括Recursion操作系统,其结合先进的基础设施层来生成专有的生物和化学数据集,以及Recursion地图,一套定制软件、算法和机器学习工具。该公司的项目包括REC-994、REC-2282、REC-4881和REC-3599。REC-994是一种口服生物可利用的超氧化物清除剂小分子,正在开发用于治疗肝硬化心肌病(CCM)。REC-2282用于治疗二型神经纤维瘤病。REC-4881用于治疗家族性腺瘤性息肉病。REC-3599用于治疗GM2神经节苷脂沉积症。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Christopher C. Gibson | Co-Founder, Chairman & Interim Executive Advisor | 2026 | 43 |
| Najat Khan | CEO, President & Director | 2026 | 41 |
| Robert M. Hershberg | Vice-Chairman & Lead Independent Director | 2026 | 64 |
| Zavain Dar | Independent Director | 2016 | 37 |
| Joseph P. Miletich | Chairman of Therapeutics Advisory Board | 2021 | 74 |
| Elaine D. Sun | Independent Director | 2025 | 53 |
| Anne Carpenter | Member of Scientific and Technical Advisory Board | 2014 | - |
| Kirk R. Thomas | Member of Scientific & Technical Advisory Board | 2014 | - |
| Dean Y. Li | Director | 2026 | 62 |
| Blake C. Borgeson | Independent Director | 2013 | 44 |
| H. Perry Fell | Member of Business Advisory Panel | 2014 | 69 |
| Robert J. Lollini | Member of Business Advisory Panel | 2014 | 72 |
| Zachary S. Bogue | Independent Director | 2018 | 51 |
| Franziska Michor | Independent Director | 2024 | 44 |
| Namandje N. Bumpus | Independent Director | 2025 | 44 |